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Although neuroglobin confers neuroprotection against Alzheimer’s disease
(AD) pathology, its expression becomes downregulated in late-stage AD.
Here, we provide evidence that indicates that this decrease is associated with
the AD-linked angiopathy. While wild-type mice of different ages show
upregulated cerebral neuroglobin expression upon whole-body hypoxia,
APP23 mice exhibit decreased cerebral transcription of neuroglobin. Interest-
ingly, transcription of cytoglobin, whose involvement in amyloid pathology
still needs to be elucidated, follows a similar pattern. To further unravel the
underlying mechanism, we examined the expression levels of the RE-1-silen-
cing transcription factor (REST/NRSF) after identifying a recognition site
for it in the regulatory region of both globins. Neuroglobin-cytoglobin-REST/
NRSF expression correlations are detected mainly in the cortex. This raises
the possibility of REST/NRSF being an upstream regulator of these globins.
Keywords: APP23; cytoglobin; hypoxia; neuroglobin; REST/NRSF
Alzheimer’s disease (AD) is a prevailing neurodegener-
ative disorder with a clinical representation of neu-
ropsychiatric disturbances and a progressive cognitive
deterioration [1]. On the histopathological level, AD
brains are typified by the emergence of insoluble neu-
rofibrillary tangles and extracellular plaques [2]. The
main building blocks of these aggregates are hyper-
phosphorylated tau protein and amyloid precursor
protein (APP)-derived b-amyloid (Ab), respectively.
However, a clear correlation between the level of senile
plaque burden and the dementia state is lacking [2].
This led to the study of soluble Ab species which are
now thought to be one of the toxic entities that drive
neuronal dysregulation, culminating in widespread
neurodegeneration [3]. Ab possesses a metal-binding
capacity, entailing the generation of reactive oxygen
species (ROS) through Fenton and Fenton-like chem-
istry [4]. Knowing the Ab burden to progressively
accumulate, it may be no surprise that antioxidant
mechanisms no longer meet with such requirements,
initiating a runaway process through ROS-related
mitochondrial damage [4,5].
Cytoglobin (Cygb) [6] and neuroglobin (Ngb) [7]
are heme proteins of the globin family with a ROS-
scavenging potential [8]. Where the involvement of
Cygb in neuroprotection is largely unexplored, Ngb
Abbreviations
Ab, b-amyloid; AD, Alzheimer’s disease; APP, amyloid precursor protein; CAA, cerebral amyloid angiopathy; Cygb, cytoglobin; Ets-1, V-ets
avian erythroblastosis virus E26 oncogene homolog 1; Hif1, hypoxia-inducible factor 1; Ngb, neuroglobin; REST, RE1-silencing transcription
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has been receiving much attention given its neuron-
specific localization [9]. Upon oxygen and glucose
deprivation, Ngb transcription is upregulated in SH-
SY5Y cells, which is associated with enhanced cell
survival [8]. Moreover, elevated Ngb levels not only
attenuate cortical hypoxic–ischemic injury in vivo
[10], but are implicated in AD as well. In vitro stud-
ies showed an increased resistance of Ngb-overex-
pressing primary neurons [11] and PC12 cells [12]
against Ab25-35-induced neurotoxicity. Ngb also
sequesters heme from Ab-heme complexes, entailing
a possible role in reducing the oxidation of neuro-
transmitters like serotonin [13]. Ngb interferes with
Ab production in vivo, reducing Ab1-40 and Ab1-42
levels in a double-cross mouse model that overex-
presses Ngb in an AD-linked background with both
the Swedish (K670N/M671L) and Indiana (V717F)
mutation [11]. In a clinical setting, however, Ngb
has only been found to be upregulated in early and
moderately advanced AD, while being reduced to
baseline levels when the pathology progresses to
more severe stages [14,15].
Interestingly, many risk factors for dementia are
linked to acute ischemic events and the impediment of
cerebral perfusion, for example, smoking, hyperten-
sion, and diabetes mellitus [16–18]. Brain infarcts have,
in particular, been identified as important modifiers of
the severity of AD clinical symptoms [19]. Moreover,
the prevalence of dementia increases from 57% to
88% [19]. In addition, neuroimaging data revealed
~ 80% more dysregulation in the cerebral vascular sys-
tem of late onset AD cases as compared to other
pathogenic events as, for example, Ab deposition and
metabolic dysfunction [20]. AD also shares features
involving white matter changes, clinical symptoms,
and pathophysiological markers with vascular demen-
tia [21]. With cerebral hypoperfusion generally forego-
ing neurodegeneration, some authors even suggested to
classify AD as a vascular pathology [16]. The detri-
mental effect lays in reduced brain Ab clearance and
its ensuing deposition in leptomeningeal and cerebral
vessel walls as cerebral amyloid angiopathy (CAA)
[22], which is observed in up to 90% of AD patients
[23]. Of note, sustained elevated ROS levels are a key
mediator of CAA and microhemorrhages as well [24].
Hence, given the additional strong link between glo-
bins and oxygen availability [25], we questioned
whether hypoxia would impact Ngb expression in
young APP23 mice to a similar extend as would vast
Ab pathology. Moreover, while functions of Cygb
entail neuroprotection, for example, detoxification of
ROS [8,26,27], its involvement in AD pathology
remained to be elucidated. We, therefore, opted to
study the alterations of Ngb and Cygb levels in APP23
mice in parallel.
Aging APP23 mice represent a valid phenocopy of
human AD, with a strong Ab pathology in the neocor-
tex and hippocampal region, and CA1 neuronal loss
reaching up to 25% in mice with a high Ab aggrega-
tion load [28,29]. CAA initiates in 8-month-old APP23
mice as focal deposits in leptomeningeal vessels [23].
The transgene—human APP with the Swedish double
mutation (K670N/M671L)—is expressed sevenfold
above endogenous APP levels and driven by the neu-
ron-specific murine Thy-1.2 promoter [28].
The present study shows for the first time Cygb
expression upregulation in normoxic cortices of 12-
month-old APP23 mice. We further detected Ngb and
Cygb transcription to be downregulated in Ab-overex-
pressing brains when the APP23 mice were subjected
to an additional hypoxic insult. To further unravel the
underlying mechanism, we studied RE-1-silencing tran-
scription factor (REST/NRSF) expression levels, for
which we identified a recognition site in the regulatory
region of both globins. Ngb-Cygb-REST/NRSF
expression correlations were detected mainly in the
cortex. These findings provide evidence for the loss of
globin-linked neuroprotection to be linked to AD
angiopathogenis, while raising the possibility of REST/
NRSF being an upstream regulator together with
hypoxia-inducible factor 1 (Hif1).
Experimental procedure
Transgenic mouse model
Male transgenic APP23 mice were studied along with wild-
type control littermates at the age of 3, 6, and 12 months.
The colony of experimental animals was maintained on a
C57BL/6J background for at least 20 generations. All pro-
cedures were approved by the animal ethics committee of
the University of Antwerp (reference number 2012-26) and
were compliant to the European Communities Council
Directive on the protection of animals used for scientific
purposes (2010/63/EU).
Hypoxia induction and reoxygenation
Experimental groups of wild-type or APP23 mice were
either (i) housed for 48 h at a normoxic oxygen concentra-
tion of 21%, (ii) housed for 48 h in a hypoxic chamber
with 7% oxygen (premixed gases: 7% O2, 93% N2) or (iii),
after the exposure to hypoxic air, reoxygenated for 6 h
under normoxic conditions, as previously described [30].
Mice of group 2 were euthanized by cervical dislocation
immediately upon removal from the hypoxic chamber.
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RNA extraction and real-time quantitative PCR
The frontal cortex and hippocampus of each mouse was
collected, snap frozen in liquid nitrogen and further pro-
cessed for total RNA. RNA was extracted, using TRIzol
Reagent in conjunction with the PureLink RNA Mini Kit
(Life Technologies, Gent, Belgium) according to the manu-
facturer’s instructions. First-strand cDNA synthesis was
performed on 1 lg of total RNA (NanoDrop; Thermo Sci-
entific, Gent, Belgium) with the GoScript Reverse Tran-
scription System (Promega, Leiden, the Netherlands) and
random primers (0.5 lg per reaction). Real-time quantita-
tive PCR was performed on a StepOnePlus system (Life
Technologies), following a 2-min incubation at 95 °C
before proceeding to 40 cycles of 95 °C for 15 s and 60 °C
for 1 min. Each real-time PCR reaction comprised Power
SYBR Green PCR Master Mix (Applied Biosystems, Halle,
Belgium), 7.5 ng cDNA (RNA equivalents), and 150 nM of




ACC, R-TGGGGGTGAATTCAGTGTGAG), Pgk1 (F-C
TCCGCTTTCATGTAGAGGAAG, R-GACATCTCCTA
GTTTGGACAGTG), Ngb (F-TACAATGGCCGCCAGT
TCT, R-TGGTCACTGCAGCATCAATCA), Cygb (F-CC
GCAGCCTACAAGGAAGTGG, R-GGGAGCTGGGAG
GGGTCTT), Hif1 (F-CGGCTCATAACCCATCAACT, R-
CAACGTGGAAGGTGCTTCA), VEGF (F-GCCTCC
CTCAGGGTTTCGG,R-CGATGATGGCGTGGTGGTG),
or REST (F-CATGGCCTTAACCAACGACAT, R-CGAC-
CAGGTAATCGCAGCAG). The four used housekeeping
genes (GAPDH, b-actin, B2M, and Pgk1) were selected from
a list of 10 reference targets, using geNorm in qBase+ (Ver-
sion 3.0; Biogazelle, Gent, Belgium), and achieved a value
V < 0.15. Inter-run calibration factors for each target were
included to remove the run-to-run difference.
Immunohistochemistry
Coronal paraffin sections of brains were immunostained
after microwave-citrate (pH6) antigen retrieval for 10 min.
Endogenous peroxidase activity within the tissue was
blocked by incubation in 1% hydrogen peroxide in metha-
nol for 30 min. After incubation in 1/25 normal goat serum
and 1% bovine serum albumin in tris-buffered saline to
block nonspecific antibody binding, slides were stained
overnight at 4 °C with primary antibody (1 : 500 Ab
ab2539, Abcam, Cambridge, UK; 1 : 100 Ngb 13499-1-AP,
Protein Tech, Manchester, UK; 1 : 100 polyclonal Cygb
[31]). Subsequently, sections were incubated with 1 : 200
goat anti-rabbit antibody (E0432; Dako, Leuven (Hever-
lee), Belgium) and further developed with the ABC Kit
(Vector Laboratories, Peterborough, UK). Images were
captured using an Olympus BX51 standard research
fluorescence microscope (Olympus, Berchem, Belgium)
equipped with an Olympus DP71 digital camera. Intensities
of staining patterns were analyzed with IMAGEJ software
(Fiji, Madison, WI, USA) and represented as optical densi-
ties; OD = log(max intensity/mean intensity).
Oxidative damage
Total brain hemisphere lysate levels of malondialdehyde,
an end product of lipid peroxidation, were studied using
the lipid peroxidation (MDA) assay kit (Biovision, Milpi-
tas, CA, USA) according to the manufacturer’s instruc-
tions. The degree of lipid peroxidation was determined with
reference to a malondialdehyde standard.
Data analysis
The relative mean transcript values for the different condi-
tions were calculated from normalized Cq values by refer-
ence to the mean of the baseline group, being the 3-month-
old wild-type mice that were housed under normoxic condi-
tions. Calculations were performed with qBase+ (Version
3.0; BioGazelle). For immunohistochemistry data, the mean
value of the cortex of the normoxic 3-month-old wild-type
mice was considered as the baseline. GRAPHPAD PRISM soft-
ware (v5.0; San Diego, CA, USA) was used for graphing
and statistical calculations. Statistical comparisons were
performed using repeated measures analysis of variance
(one-way ANOVA) with Bonferroni’s post hoc testing or
Student’s t-testing, as indicated. P-values below 0.05 were
considered statistically significant. All data are depicted as
the mean  standard error of the mean (SEM).
Results
Ab accretion and lipid peroxidation impact
neuroprotective globin levels
To be able to follow the progression of pathology, we
studied amyloid immunoreactivity in the cortex and
hippocampus of APP23 mice and wild-type control lit-
termates at the age of 3, 6, and 12 months. The hip-
pocampus shows higher Ab protein staining intensities
than the cortex and the cerebral Ab load significantly
increases only in the hippocampus (t = 4.174 Bonfer-
roni, Fig. 1D). Given lipid peroxidation to be an early
event in AD development and to be a major product
of free radical-mediated damage [32], we also quanti-
fied the levels of malondialdehyde, an end product of
lipid peroxidation (Fig. 1E). The severity of both these
inductors of cellular stress was correlated with the cor-
tical and hippocampal transcription level of Cygb and
Ngb (as comparison). APP23 mice of 12 months of
age showed a 2.43  0.21-fold increase in Cygb
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expression in the frontal cortex, similar to the upsurge
in Ngb transcription (Fig. 1A). Such an effect was not
detected at the age of 3 and 6 months, that is, before
the onset of plaque formation (Fig. 1D) and the
kick-in of oxidative stress (Fig. 1E). In contrast to the
frontal cortex, none of the studied neuroprotective
transcripts was significantly upregulated in the
hippocampus (Fig. 1B).
Next, we studied the relationship between the glo-
bins’ mRNA and protein levels, confirming that the
Ngb protein staining pattern intensity increases at the
onset of pathology (1.48  0.19-fold increase in cor-
tices of 1-year-old APP23 mice, data not shown).
However, we are the first too show that the optical
density of the Cygb protein staining is also upregu-
lated by 1.29  0.02- and 1.13  0.06-fold in the
Fig. 1. Influence of Ab deposition and lipid peroxidation on increases in neuroprotective Ngb and Cygb. (A) Cortical and (B) hippocampal
real-time qPCR data of murine Cygb, Ngb, and VEGF expression levels of wild-type mice (n = 4 per group) and APP23 mice (n = 4 per
group) under normoxic conditions. (C) High-power photomicrographs represent 20 9 magnified pictures of Cygb immunohistochemistry.
Optical densities relative to the 3-month-old wild-type cortex are listed below. The scale bar represents 100 lm. Intensities show a disease
progression-dependent upregulation, that is, upon limited plaque burden (D, n ≥ 2) and in the presence of oxidative damage (E, n = 3). Data
are depicted as the mean  SEM. Statistical significance was tested using one-way ANOVA with Bonferroni post hoc test; *P < 0.05,
**P < 0.01, ***P < 0.001.
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cortex and hippocampus of 12-month-old APP23 mice,
respectively. Of note, these elevations in Cygb protein
levels correlate less with disease stage as those of Ngb,
that is, they are not significantly different from those
of the earlier 3 and 6 month time points (Fig. 1C).
Wild-type animals show a more pronounced
hypoxia-counteracting transcriptional response
Next, we sought to elucidate whether hypoxic events
could underlie the previously observed downregulation
of Ngb expression in the later stages of AD pathology
[14,15]. Moreover, we aimed to examine if a similar
impact of experimentally induced hypoxia could be
detected on Cygb levels in limited Ab-stressed brains.
Hence, mice of both genotypes and different ages were
subjected to a general hypoxic insult of 7% oxygen for
48 h. Wild-type mice showed the expected increase in
globin expression ([10,33,34], Fig. 2A). In APP23 mice
of 3- and 6-months, however, Cygb and Ngb tran-
script levels stayed unaltered in comparison to the nor-
moxic condition (Fig. 2A). Moreover, the globin
expression levels were significantly lowered in the fron-
tal cortex as compared to the normoxia group at
1 year (up to 0.62-fold). Interestingly, mice of the
same genotype but from different age groups did not
display a difference in cerebral oxidative stress level
upon the hypoxic insult, as can be deducted from the
lipid peroxidation levels (Fig. 2D, ANOVA:
P = 0.0572 for wild-type mice and P = 0.1370 for
APP23 mice). On the contrary, strong to very strong
positive relationships were detected between VEGF
Fig. 2. Withdrawal of Ngb expression upregulation upon hypoxia in APP23 brain. Cortical and hippocampal transcript (A,B) levels of murine
Cygb and Ngb after (A) 48 h of hypoxia and (B) 48 h of hypoxia, followed by 6 h of reoxygenation. Data of wild-type and APP23 mice (n = 4
per group) are depicted as the mean  SEM and represent values relative to the age/genotype-matched normoxic condition. Numbers
above horizontal bars represent mean values relative to the baseline (values of 3-month-old, normoxic wild-type mice). Significant
differences with the baseline are defined as P < 0.05, according to Student’s t-test and depicted above rectangles. Other statistical
significances were tested using one-way ANOVA with Bonferroni post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001. (C) Hippocampal
expression levels of VEGF. (D) Quantitation of malondialdehyde (n = 3 per group), representing an end product of lipid peroxidation, in total
brain hemisphere lysates. Given the lack of age-dependent differences, the values of all wild-type and APP23 mice were combined.
1325FEBS Letters 591 (2017) 1321–1332 ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Z. P. Van Acker et al. Alterations in neuroprotective globin levels
and globin transcript levels across the different condi-
tions (Table 1). These results indicate that the differ-
ences in globin transcription, that are perceived under
hypoxia across the different age groups, are not driven
by differences in lipid peroxidation levels, but rather
can be attributed to other cellular dysregulations, for
example, due to amyloid metabolism dysfunctions and
VEGF signaling. Of note, although Cygb levels are
lowered in the 1-year-old APP23 frontal cortices upon
hypoxia induction, their levels are still retained above
the level of 3-month-old, normoxic wild-type mice
(1.52-fold, Fig. 2B). As for reinduction of globin
expression after reoxygenation, the data of the hip-
pocampus reveal a broader upregulation across the dif-
ferent conditions than the cortex (Fig. 2B).
In contrast to the transcriptional level where
hypoxia reduces globin expression in APP23 mice,
Ngb and Cygb protein levels are slightly elevated
across all studied ages and in both the cortex and hip-
pocampus of APP23 mice (Fig. 3A). The upregulation
is paralleled with the lower degree of peroxidation as
compared to the one of wild-type mice (Fig. 2D). Of
note, increases in protein staining after hypoxia and
reoxygenation are higher for Cygb than for Ngb
(Fig. 3A/B).
Influence of RE1-silencing transcription factor
expression on globin transcription
To further unravel the underlying mechanism, we
searched for REST interactions with globin regulatory
sequences. First, the regions upstream of the Ngb and
Cygb promotors were scanned for predicted REST-
binding sites using the MA0138.2 REST-binding
profile on jaspar.genereg.net (Fig. 4A). This
search revealed not only a REST transcription factor-
binding site before the Ngb promotor (Fig. 4B,
chr12:87110424-87110444), but also in the Cygb regu-
latory region (Fig. 4B, Chr11:116653849-116653869).
Moreover, ChIP-seq data on the UCSC Genome
Browser (Human Feb. 2009 GRCh37/hg19 Assembly)
show REST binding to the regulatory region upstream
of the Ngb promotor in H1-hESC cells. Hence, we
analyzed the expression levels of REST across the dif-
ferent experimental groups. Given that REST
activation can be both gene transcription inducing and
downregulating, Fig. 4 depicts the differences in REST
expression levels between wild-type and APP23 mice.
REST expression does not differ between normoxic
wild-type and APP23 hippocampi across the different
age groups (Fig. 4C). In the cortex, however, the dif-
ference in transcription between both genotypes
increases with aging (Fig. 4C). This brain region-speci-
fic expression alteration corresponds with the age-
dependent upsurge in cortical globin expression, which
was not seen in the hippocampal area (Fig. 1A/B).
After the hypoxic insult, cortical REST expression
levels of wild-type and APP23 mice differ most clearly
at the 3- and 12-month time points (Fig. 4D), which is
also observed for globin transcription levels (Fig. 2A,
capped lines between rectangles). The difference in
wild-type and APP23 hippocampal expression of
REST diminishes with age (Fig. 4D). Such a trend is
seen for hippocampal Cygb expression as well, with
the difference in fold change lowering from 1.04 over
0.34 to 0.13 (Fig. 2A). Ngb expression during hypoxia
appears to deviate from this pattern, with the differ-
ence between genotypes being highest at the 3- and 12-
month time points, as was the case for the cortical
area (Fig. 2A, capped lines between rectangles).
Nonetheless, hypoxic REST transcript levels are gener-
ally lowered relative to the age- and genotype-matched
normoxic levels in both brain areas from 6 months
onwards (Fig. 4F). After reoxygenation, expression
levels of REST and globins correlate less.
Discussion
Over the past 15 years, the genetics, structure, evolu-
tion, and biological functions of Cygb and Ngb have
been intensively studied across the phylogenetic tree.
In addition to the maintenance of cellular oxygen sup-
ply, a scala of physiological implications has been pro-
posed for both globins, including the involvement in
signal transduction, the detoxification of reactive oxy-
gen or nitrogen species and the counteraction of
Table 1. Pearson’s correlation coefficients across the different oxygen availability conditions.
Correlation
VEGF: frontal cortex VEGF: hippocampus
Normoxia Hypoxia Reoxygenation Normoxia Hypoxia Reoxygenation
Cygb 0.55 0.64 0.62 0.65 0.47 0.71
Ngb 0.38 0.66 0.74 0.59 0.74 0.63
r ≥ +0.70, very strong positive relationship; r = +0.40 to +0.69, strong positive relationship; r = +0.30 to +0.39, moderate positive relation-
ship; r = +0.20 to +0.29, weak positive relationship; r = +0.01 to +0.19, no or negligible relationship.
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cytochrome c-induced apoptosis [25]. Moreover, as
mentioned in the introduction, transgenic overexpres-
sion of Ngb in the APP Swedish-Indiana double-muta-
tion mouse model reduced the Ab(1–40) load, restored
somal microdomain distribution, and ameliorated per-
formance in the Y-maze [11]. Despite its neuroprotec-
tive traits, Ngb transcription is downregulated to
baseline levels in cases of severe AD pathology [14,15].
As later stage AD is characterized by a lowered oxy-
gen availability due to CAA [16,22,23], we questioned
whether whole-body hypoxia as a secondary insult
could likewise downregulate Ngb and Cygb expression
in young APP23 mice.
Upregulated cellular Ngb levels in AD-affected cells
have been described before. In particular, Ngb protein
levels in patients with early and moderately advanced
AD were detected to be increased by 23% in the supe-
rior temporal lobes [15]. Ngb immunoreactivity further
revealed the elevations in the cerebral cortex to be
localized to both the cytoplasm of cell bodies and
extracellular plaque-like structures [14]. To the best of
our knowledge, this paper is the first to report an
upregulation of Cygb levels in 12-month-old, normoxic
APP23 cortices. In contrast to the upregulated globin
expression in the cortex, we detected no alterations in
APP23 hippocampal Ngb and Cygb transcription
rates. As a trend of increased VEGF expression was
also noticed in the cortex, but not in hippocampus, the
latter could be attributed to the positive correlation
between both globins and VEGF, which we detected
across all studied conditions. Our observation of
increased neuroprotective VEGF levels to be brain
region specific is in line with the literature, which
describes VEGF involvement to comprise the cerebral
cortex and cerebrospinal fluid [35]. Hence, Ngb and
Cygb involvement in AD pathology could be strongly
linked to Hif1 and VEGF expression. It is, however,
likely that a variety of different transcription factors
and upstream signals together elicit the observed glo-
bin expression patterns.
Binding sequences for REST, also known as Neu-
ron-Restrictive Silencer Factor, have been identified
before in the regulatory region of Ngb, using both
rVista 2.0 [36] and MSCAN [37]. To the best of our
knowledge, we are the first to identify a recognition
sequence in the regulatory region of Cygb as well.
REST expression is induced during normal brain aging
and its activation generally entails neuroprotection by
downregulating targets involved in cell death [38].
However, transcription of REST is markedly reduced
in AD-affected neuronal populations [38,39]. More-
over, REST increases transcription of genes related to
Fig. 3. Increased globin protein levels upon and after hypoxia in wild-type and APP23 brain. Cortical and hippocampal protein (A,B) levels of
murine Cygb and Ngb after (A) 48 h of hypoxia and (B) 48 h of hypoxia, followed by 6 h of reoxygenation. Data of wild-type and APP23
mice (n ≥ 2 per group) are depicted as the mean  SEM and represent values taken relative to the age/genotype-matched normoxic
condition. Numbers above horizontal bars represent mean values relative to the baseline, that is, the mean value of the cortex of the
normoxic 3-month-old wild-type mice. Significant differences compared to baseline values are defined as P < 0.05, according to Student’s t-
test and depicted above rectangles. Other statistical significances were tested using one-way ANOVA with Bonferroni post hoc test;
*P < 0.05, **P < 0.01, ***P < 0.001.
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neurotransmission in the early stages of AD. In later
stages, these genes are suppressed [38]. Given the dual
and opposing effects of REST, no consensus is reached
yet on whether upregulated REST levels are protective
or detrimental [40]. Hence, we opted to focus on dif-
ferences in transcription levels of REST between nor-
moxic wild-type and APP23 mice. In doing so, we
detected altered expressions in frontal cortices of 1-
year-old APP23 mice for Ngb, Cygb, and REST, while
hippocampal levels of all three genes remained rela-
tively unchanged as compared to the wild-type levels.
These findings strengthen the hypothesis of REST/
NRSF regulating globin expression together with Hif1/
VEGF along the AD pathology.
In advanced AD stages, Ngb transcript levels in the
CA1 region of the hippocampus were reported to
return to values found in healthy control subjects [14].
In the present study, we identified a comparable
decrease to baseline expression in 3-, 6-, and 12-
month-old APP23 mice when they were subjected to
whole-body hypoxia. Based on our observations, we
postulate the following two hypotheses: (i) the Ngb
promotor activity is downregulated when a threshold
degree of cellular damage/dysregulation is reached
and/or (ii) hypoxia and vast amyloid aggregation
pathology effectuate a convergent pathway that inter-
feres with the activity of an inducer of Ngb expression.
Interestingly, hypoxia induces the miR-106b~25 cluster
that downregulates REST in LNCaP and PC3 prostate
cancer cell lines [41]. We identified REST expression
levels to be decreased relative to age- and genotype-
matched normoxic levels, although this downregula-
tion was only seen in animals aged ≥ 6 months. Hence,
as similar for the normoxic groups, the globin expres-
sion patterns are more likely the result of a triad of
upstream signals, for example, related to Hif1 as well.
In contrast to the downregulation of Ngb in hypoxic
APP23 brains, Cygb transcript levels remain elevated
relative to the normoxic condition. The reason as to
why Cygb expression is able to overcome such
Fig. 4. Linking RE1-Silencing Transcription factor to globins. (A) Profile of the REST transcription factor-binding sequence (ID: MA0138.2
from the JASPAR CORE database). (B) Predicted REST-binding sequences and their positions in the regulatory regions of the Ngb and Cygb
genes. Mean differences  SEM between wild-type and APP23 expression levels of REST under (C) normoxia, (D) hypoxia, and (E) after
reoxygenation (n ≥ 3 per group). (F) Mean fold change values of wild-type and APP23 mice (n = 3–4 mice per group) relative to the
genotype- and age-matched normoxic condition.
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negative regulation could be the confirmation of our
previous finding of a strong positive relationship
between Cygb and VEGF [34]. VEGF was chosen over
Hif1 as Hif1 is regulated to a large extent at the post-
mRNA level [42]. The cross-talk between Ngb and
Hif1/VEGF, on the other hand, is indirect through the
specificity protein 1 (Sp1) transcription factor [43].
However, we also detected a generally lower transcrip-
tional response of Cygb expression alteration in the
3-month-old APP23 mice as opposed to those of the
1-year time point. It is possible that due to AD-linked
cellular dysregulations, some kind of prior history of
hypoxia (e.g., amyloid angiopathy) is required to trig-
ger an upregulation in Cygb transcription. Such phe-
nomenon could be similar to hypoxic preconditioning
in which sublethal stress endorses (neuro)protective
actions against acute injuries [44]. The latter would be
consistent with the Cygb promotor containing a V-ets
avian erythroblastosis virus E26 oncogene homolog 1
(Ets-1) site [45]. Ets-1 is upregulated in cortices and
hippocampi of AD patients, surmounted by Ets-1
being strongly connected with angiogenic markers as
VEGF [46].
In contrast to their transcript levels, the Ngb and
Cygb protein levels in APP23 mice are all elevated
after hypoxia and reoxygenation, thereby paralleling
lipid peroxidation levels. Sustained protein levels could
be attributed to Ab oligomers impairing the protea-
some and, hence, favoring a low protein turnover.
Decreased proteasome functioning already occurs in
prepathological disease stages in 3xTg-AD mice [47].
In APP23 mice, we recently detected an age-genotype
interaction effect on expression levels of genes enriched
for modules of the lysosomal pathway, the degradation
by proteases and the proteasome (e.g., Psmb9) [48].
The decrease in rodent proteasome activity is a good
phenocopy of the human situation in which proteaso-
mal inhibition reaches up to 48% in AD brains [49].
Furthermore, AD is not only characterized by a
lysosomal blockage caused by Ab, but cathepsin D
transcript and protein levels are both reduced in AD-
affected cells as well [50,51]. As a consequence, globin-
linked neuroprotection could be extended beyond
stages with reduced transcript levels. We do not
exclude that post-transcriptional regulations take into
effect, hence impacting globin protein levels as well. In
particular, a discrepancy between Cygb/Ngb transcript
and protein levels was observed before [52,53]. More-
over, the involvement of Cygb in AD pathology had
not yet been described, with the exception of it being
present in eosinophilic cytoplasmic inclusions [54].
Ngb immunoreactivity in AD cortices also exhibits a
punctate distribution outside cell bodies, in addition to
being elevated within neurons [14]. Hence, it should
Fig. 5. Scheme summarizing the proposed hypothesis for Ngb (post)transcriptional regulation. Hypoxia-induced Ngb expression is
hypothesized to work through the HIF1-Sp1-Ngb axis as the Ngb promotor lacks a direct-binding site for HIF1, but contains a Sp1-binding
GC-box [36,43]. Moreover, Sp1 is known to participate downstream of HIF1 in sequential gene activation upon cerebral ischemia [56].
Another transcription factor regulating Ngb expression is REST. Its upregulation is paralleled with aging, largely ascribed to cell
nonautonomous Wnt signaling. However, REST can get trapped with pathological misfolded proteins, including Ab, losing its nuclear levels
and downstream neuroprotective actions [38]. REST is also downregulated by hypoxia-induced miRNAs [41]. Hence, we hypothesize the co-
occurrence of both nuclear REST-depleting events in hypoxic APP23 brains to outweigh Ngb expression-inducing signals. Of note, Ab
oligomers impair proteasome function as from prepathological disease stages, that is, 3 months in transgenic mice [47]. The latter makes
us postulate that the discrepancy between transcript and protein levels in hypoxic APP23 brains is caused by a blocked proteasomal
function, favoring a low protein turnover. If still physiologically available, the sustained Ngb levels could entail a prolonged neuroprotective
action being carried out. CREB, cAMP response element-binding protein; Hif1, hypoxia-inducible factor 1; REST, RE1-silencing transcription
factor; ROS, reactive oxygen species; SP1, specificity protein 1.
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not be excluded that Cygb and Ngb become (in part)
physiologically unavailable in later stages of AD
pathology.
A combination of reduced protein turnover, REST
activation patterns and Hif1 activation could underlie
our observations, leading to a novel hypothesis
concerning Ngb (post)transcriptional regulation as
depicted in Fig. 5. Even though such a pathway seems
to emerge from our obtained data, additional experi-
ments will be required to fully support this hypothesis.
Since REST has the potency to be both activating and
inhibiting with regard to gene expression [38,40,55], its
influence on globin expression requires further research
to allow absolute expression levels of REST to be cor-
related with globin transcription. The latter would also
require data on REST protein levels and knowledge
on its subcellular localization. In cases of aggregation
pathologies, for example, AD and frontotemporal
lobar degeneration, REST appears trapped in cyto-
plasmic inclusions [38].
In conclusion, our data point for the first time to a
possible widening of the neuroprotective traits of Cygb
to AD pathology and to Cygb being strongly associ-
ated with VEGF angiopathogenic alterations. More-
over, we showed that hypoxia up- and downregulates
globin expression in young, wild-type, and APP23
mice, respectively. Given the genotype- and brain
region-specific expression of REST, we hypothesize
REST activation patterns to also contribute to globin
expression alterations.
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